comparemela.com
Home
Live Updates
CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY : comparemela.com
CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY
Please disregard the headline "Gilead Sciences Proposed to Acquire CymaBay for $32.50 Per Shr in Cash or a Total Equity Value of $4.3B," at 4:46 p.m. ET. The...
Related Keywords
,
Gilead Sciences Proposed To Acquire Cymabay ,
Sciences Proposed ,
Acquire Cymabay ,
Total Equity Value ,
Article Normal ,
Biotechnology Services ,
Pharmaceuticals ,
Healthcare Life Sciences ,
Biopharmaceuticals ,
Synd ,
Cymabay Therapeutics ,
Cbay ,
Us23257d1037 ,
Us3755581036 ,
Gild ,
Healthcare ,
Life Sciences ,
comparemela.com © 2020. All Rights Reserved.